Gretchen S. Chidester^{a*}, Boyd B. Scott^b, Keith J. Gaddie^c, Ken Truman^d, and Jamie L. Kistler^e

^aBiogen, Cambridge, MA, USA ^bMerck & Co., Inc., Kenilworth, NJ, USA ^cVertex Pharmaceuticals, Boston, MA, USA ^dMedThink SciCom, Cary, NC, USA ^eParexel International, Newton, MA, USA *Affiliation at time of survey development, data collection, and data analysis: MedThink SciCom.

Poster 38 Join us

for a candid conversation with the authors

KEY FINDINGS

- Experience with formal assessment of SCPs, particularly externally focused metrics, was limited among ISMPP survey respondents
- Potential barriers cited included organizational structure, logistics, budget, and lack of familiarity with defining appropriate metrics
- Industry professionals generally agreed that it would be of value to define a series of metrics, including both internally and externally focused assessments, to measure the success of an SCP



CONCLUSIONS

- Survey results indicated general alignment regarding how to define SCP success but reveal a lack of consistency in how to define and implement specific metrics to assess this success in a meaningful way
- Although various barriers have precluded broad adoption of SCP metrics to date, respondents acknowledged the value of designing appropriate metrics and indicated a desire to learn how to define and implement appropriate metrics through future ISMPP educational programs

INTRODUCTION

We conducted a survey of ISMPP membership to:



understand how industry professionals define the success of SCPs



assess current trends regarding use of metrics



identify barriers to implementation of formal metrics



METHODS

0000

- A survey targeting industry professionals with experience in SCP development was posted to ISMPP LinkedIn and ISMPP Connect forums; authors also posted the survey link to professional networks
- Responses were collected between 11/24/2020 and 12/14/2020
- Survey respondents were categorized into groups:
 - "Pharmaceutical": affiliated with small/midsize or large pharmaceutical companies, or medical device companies
 - "Nonpharmaceutical": affiliated with medical communications agencies, other solutions provider companies, academia, publisher, other






How do ISMPP members define success of an SCP?

- 91 respondents from >35 different organizations initiated the survey
- Of these, ~20 pharmaceutical and ~30 nonpharmaceutical respondents provided responses to key questions of interest and reported having recent experience with the development of SCPs
- Limited responses to some key questions of interest may suggest minimal experience to date with assessing the success of SCPs using formal metrics

Survey respondents reported limited current use of metrics to assess success of the SCP

■ Use of specific metrics to measure success was low: 5/20 (25%) pharmaceutical respondents reported current use of specific metrics, and 11/30 (36%) nonpharmaceutical respondents reported that some or all of their current clients used such metrics



^aData represent proportion of responses from 20 pharmaceutical respondents who answered this question. ^bData represent proportion of responses from 30 nonpharmaceutical respondents who answered this question.

- Commonly reported metrics used included visits to a web-based SCP (pharmaceutical 3/6 [50%]; nonpharmaceutical, 6/11 [55%]) and assessment of lexicon use within internal documents (pharmaceutical, 1/6 [17%]; nonpharmaceutical 6/11 [55%]) and external documents (pharmaceutical, 3/6 [50%]; nonpharmaceutical, 5/11 [45%])
- $\mathbf{\Theta}$

 $\mathbf{\Theta}$

Ð

Use of externally focused metrics was very low among respondents, suggesting limited experience to date; survey respondents primarily cited literature tracking and manual analysis to report on language/lexicon utilization Across groups, SCP success was defined as consistent implementation of the SCP into cross-functional workstreams, alignment of key deliverables with the SCP, and adoption of select SCP components by external stakeholders


Responses to survey question, "How do you define the success of an SCP? In an ideal world, what type of information would you want to be able to measure to assess this success?" Representative examples from pharmaceutical and nonpharmaceutical respondents are shown.

Adoption of lexicon and scientific story by HCPs/expert as demonstrated Aspirational language in the SCP being through their communication activities used as a foundation for future evidence independent of the company generation and publications Language developed and evidence Implementation across all functions and used for the SCP ... used across the departments of the internal team compound franchise Users become familiar with key Internal and external facing evidence relating to the product and, communications are aligned to the although it is not intended as a key SCPs scientific statements, lexicon, message document, that the messaging and references of publications would be consistent across functions as a result of clearly structured concepts in the SCP

Thinking ahead to the future of SCPs: Metrics matter

Developing an SCP is a large undertaking, which can often take a significant • amount of time, resources, and/or budget. While metrics are extremely important to demonstrate the impact of such an initiative, they are not always consistently defined (not really followed through on at the completion of the SCP). It would be important to really define, for each team involved in SCP development and implementation, what success might look like and how they want to measure success as part of the early stages of SCP development. Should really include metrics as part of the overall project plan and think about how these assessments might be carried out after final implementation.

– ISMPP Survey Respondent



ACKNOWLEDGMENTS The authors wish to thank all ISMPP survey participants for their time and valuable insights, as well as Parexel International for editorial, graphics, digital, and production support in the development of this interactive poster and MedThink SciCom for editorial and graphics support for our corresponding ISMPP Annual Meeting parallel session.

Gretchen S. Chidester^{a*}, Boyd B. Scott^b, Keith J. Gaddie^c, Ken Truman^d, and Jamie L. Kistler^e

CONCLUSIONS

^aBiogen, Cambridge, MA, USA ^bMerck & Co., Inc., Kenilworth, NJ, USA ^cVertex Pharmaceuticals, Boston, MA, USA ^dMedThink SciCom, Cary, NC, USA ^eParexel International, Newton, MA, USA *Affiliation at time of survey development, data collection, and data analysis: MedThink SciCom.

Poster 38

Join us for a candid conversation with the authors

KEY FINDINGS

- Experience externally fo respondents
- Potential bar budget, and
- Industry provide to define and external success of a s











A Candid Conversation With the Authors



For additional perspectives from the authors on this topic, please view the OnDemand Parallel Session

Metrics Matter: Determining the Success of Your Scientific Communication Platform



https://bit.ly/3cQHcA2

egarding how to nsistency in how to assess this success

l broad adoption of wledged the value of ted a desire to learn metrics through

erience in SCP SMPP Connect forums; networks nd 12/14/2020

r large pharmaceutical

mmunications academia,



 Of these, ~20 pl provided respondence with

available starting Monday, April 12

Disclaimer: Information presented reflects the personal knowledge and opinion of the presenters and does not necessarily represent the position of their current or past employers or the position of ISMPP.

•


ementation of the SCP ples with the SCP, and

n SCP? In an ideal world, assess this success?"

Limited responses to some key questions of interest may suggest minimal experience to date with assessing the success of SCPs using formal metrics

Survey respondents reported limited current use of metrics to assess success of the SCP

Use of specific metrics to measure success was low: 5/20 (25%) pharmaceutical respondents reported current use of specific metrics, and 11/30 (36%) nonpharmaceutical respondents reported that some or all of their current clients used such metrics




^aData represent proportion of responses from 20 pharmaceutical respondents who answered this question. ^bData represent proportion of responses from 30 nonpharmaceutical respondents who answered this question.

Commonly reported metrics used included visits to a web-based SCP (pharmaceutical 3/6 [50%]; nonpharmaceutical, 6/11 [55%]) and assessment of lexicon use within internal documents (pharmaceutical, 1/6 [17%]; nonpharmaceutical 6/11 [55%]) and external documents (pharmaceutical, 3/6 [50%]; nonpharmaceutical, 5/11 [45%])



 Θ

Use of externally focused metrics was very low among respondents, suggesting limited experience to date; survey respondents primarily cited literature tracking and manual analysis to report on language/lexicon utilization



Thinking ahead to the future of SCPs: Metrics matter

structured concepts in the SCP

Developing an SCP is a large undertaking, which can often take a significant amount of time, resources, and/or budget. While metrics are extremely important to demonstrate the impact of such an initiative, they are not always consistently defined (not really followed through on at the completion of the SCP). It would be important to really define, for each team involved in SCP development and implementation, what success might look like and how they want to measure success as part of the early stages of SCP development. Should really include metrics as part of the overall project plan and think about how these assessments might be carried out after final implementation.

- ISMPP Survey Respondent

ACKNOWLEDGMENTS The authors wish to thank all ISMPP survey participants for their time and valuable insights, as well as Parexel International for editorial, graphics, digital, and production support in the development of this interactive poster and MedThink SciCom for editorial and graphics support for our corresponding ISMPP Annual Meeting parallel session.

Gretchen S. Chidester^{a*}, Boyd B. Scott^b, Keith J. Gaddie^c, Ken Truman^d, and Jamie L. Kistler^e

^aBiogen, Cambridge, MA, USA ^bMerck & Co., Inc., Kenilworth, NJ, USA ^cVertex Pharmaceuticals, Boston, MA, USA ^dMedThink SciCom, Cary, NC, USA ^eParexel International, Newton, MA, USA *Affiliation at time of survey development, data collection, and data analysis: MedThink SciCom.

Poster 38 Join us **A** for a candid conversation with the authors

KEY FINDINGS CONCLUSIONS Survey results indicated general a Experience with formal assessment of SCPs, particularly egarding how to sistency in how to externally fo sess this success respondents **SUMMARY** Potential ba broad adoption of budget, and wledged the value of Industry pro ted a desire to learn value to defi metrics through and externa success of The role of the SCP as a **Development and implementation** However, current formal strategic scientific foundation assessment of SCP success of appropriate internally and externally focused metrics for a product or therapeutic area is limited INTRODUCT requires identification of specific is well understood questions with actionable answers erience in SCP We conducted Industry professionals generally Organizational structure, logistics, SMPP Connect forums; agree that it would be of value and a lack of familiarity with Advances in technology and networks defining metrics may contribute available tools (eg, web-based to define a series of metrics to under nd 12/14/2020 to this lack of formal assessment platforms, Al) provide new measure the success of an SCP defi opportunities for the development of relevant qualitative and r large pharmaceutical asses quantitative metrics mmunications iden cademia, \oplus to im




How do ISMPP members define success of an SCP?

- 91 respondents from >35 different organizations initiated the survey
- Of these, ~20 pharmaceutical and ~30 nonpharmaceutical respondents provided responses to key questions of interest and reported having recent experience with the development of SCPs
- Limited responses to some key questions of interest may suggest minimal experience to date with assessing the success of SCPs using formal metrics

Survey respondents reported limited current use of metrics to assess success of the SCP

Use of specific metrics to measure success was low: 5/20 (25%) pharmaceutical respondents reported current use of specific metrics, and 11/30 (36%) nonpharmaceutical respondents reported that some or all of their current clients used such metrics




^aData represent proportion of responses from 20 pharmaceutical respondents who answered this question. ^bData represent proportion of responses from 30 nonpharmaceutical respondents who answered this question.

- Commonly reported metrics used included visits to a web-based SCP (pharmaceutical 3/6 [50%]; nonpharmaceutical, 6/11 [55%]) and assessment of lexicon use within internal documents (pharmaceutical, 1/6 [17%]; nonpharmaceutical 6/11 [55%]) and external documents (pharmaceutical, 3/6 [50%]; nonpharmaceutical, 5/11 [45%])
- Θ

 Θ

•

Use of externally focused metrics was very low among respondents, suggesting limited experience to date; survey respondents primarily cited literature tracking and manual analysis to report on language/lexicon utilization



Responses to survey question, "How do you define the success of an SCP? In an ideal world, what type of information would you want to be able to measure to assess this success?" Representative examples from pharmaceutical and nonpharmaceutical respondents are shown.

generation and publications Language developed and evidence used for the SCP ... used across the

Aspirational language in the SCP being

compound franchise

used as a foundation for future evidence


Adoption of lexicon and scientific story by HCPs/expert as demonstrated through their communication activities independent of the company

Implementation across all functions and departments of the internal team

Users become familiar with key evidence relating to the product and, although it is not intended as a key message document, that the messaging of publications would be consistent across functions as a result of clearly structured concepts in the SCP

Internal and external facing communications are aligned to the SCPs scientific statements, lexicon, and references

Thinking ahead to the future of SCPs: Metrics matter



– ISMPP Survey Respondent

ACKNOWLEDGMENTS The authors wish to thank all ISMPP survey participants for their time and valuable insights, as well as Parexel International for editorial, graphics, digital, and production support in the development of this interactive poster and MedThink SciCom for editorial and graphics support for our corresponding ISMPP Annual Meeting parallel session.

Gretchen S. Chidester^{a*}, Boyd B. Scott^b, Keith J. Gaddie^c, Ken Truman^d, and Jamie L. Kistler^e

^aBiogen, Cambridge, MA, USA ^bMerck & Co., Inc., Kenilworth, NJ, USA [°]Vertex Pharmaceuticals, Boston, MA, USA ^dMedThink SciCom, Cary, NC, USA ^eParexel International, Newton, MA, USA *Affiliation at time of survey development, data collection, and data analysis: MedThink SciCom.

Survey results indicated general alignment regarding how to

define SCP success but reveal a lack of consistency in how to

define and implement specific metrics to assess this success

SCP metrics to date, respondents acknowledged the value of

Although various barriers have precluded broad adoption of

Poster 38

Join us for a candid conversation with the authors

KEY FINDINGS

- Experience with formal assessment of SCPs, particularly externally focused metrics, was limited among ISMPP survey respondents
- Potential barriers cited included organizational structure, logistics, budget, and lack of familiarity with defining appropriate metrics
- Industry professionals generally agreed that it would be of value to define a series of metrics, including both internally


and external success of

INTRODUCTION









Over the past decade, industry professionals have refined SCP development processes and focused on ensuring leadership buy-in, cross-functional partnership and understanding of the value of SCPs, and rollout of the SCP in a user-friendly format to facilitate broad utilization and successful implementation

Scientific Communication Platforms (SCPs)

The SCP provides a strategic scientific foundation for a product's medical communication plan and all initiatives generated from it



CONCLUSIONS

in a meaningful way

designing appropriate metrics and

how to define and implement app

STATEMENTS



SCIENTIFIC

erience in SCP SMPP Connect forums; networks nd 12/14/2020

d a desire to learn

etrics through

r large pharmaceutical

mmunications cademia,






RESULTS

- Of these, ~20 pl provided respon experience with
- Limited respon minimal experie using formal me

LEXICON SUMMARY 1. Kistler JL. Scientific communication platform (SCP) development 101. Parallel Session at 2018 ISMPP Annual Meeting. 2. Parker T, et al. Scientific platforms 201: successful implementation of a scientific communication platform. Parallel Session at 2018 ISMPP Ann 3. Chidester G, et al. Scientific communication platforms: highlighting current best practices. The MAP. 2019. 4. Kistler JL, et al. Scientific platforms: development and successful implementation. Workshop at 2019 ISMPP Annual Meeting. Survey respondents reported limited current use of metrics used as a foundation for future evide generation and publications to assess success of the SCP

Use of specific metrics to measure success was low: 5/20 (25%) pharmaceutical respondents reported current use of specific metrics, and 11/30 (36%) nonpharmaceutical respondents reported that some or all of their current clients used such metrics



^aData represent proportion of responses from 20 pharmaceutical respondents who answered this question. ^bData represent proportion of responses from 30 nonpharmaceutical respondents who answered this question.

- Commonly reported metrics used included visits to a web-based SCP (pharmaceutical 3/6 [50%]; nonpharmaceutical, 6/11 [55%]) and assessment of lexicon use within internal documents (pharmaceutical, 1/6 [17%]; nonpharmaceutical 6/11 [55%]) and external documents (pharmaceutical, 3/6 [50%]; nonpharmaceutical, 5/11 [45%])

 Θ

Use of externally focused metrics was very low among respondents, suggesting limited experience to date; survey respondents primarily cited literature tracking and manual analysis to report on language/lexicon utilization



		lementation of the SCP
		bles with the SCP, and
inual	Meeting.	rs an SCP? In an ideal world, o assess this success?" al respondents are shown.
		lexicon and scientific story pert as demonstrated
enco	e	through their communication activities independent of the company


Language developed and evidence Implementation across all functions and used for the SCP ... used across the departments of the internal team

Users become familiar with key evidence relating to the product and, although it is not intended as a key message document, that the messaging of publications would be consistent across functions as a result of clearly structured concepts in the SCP

compound franchise

Internal and external facing communications are aligned to the SCPs scientific statements, lexicon, and references

Thinking ahead to the future of SCPs: Metrics matter



– ISMPP Survey Respondent

ACKNOWLEDGMENTS The authors wish to thank all ISMPP survey participants for their time and valuable insights, as well as Parexel International for editorial, graphics, digital, and production support in the development of this interactive poster and MedThink SciCom for editorial and graphics support for our corresponding ISMPP Annual Meeting parallel session.

Gretchen S. Chidester^{a*}, Boyd B. Scott^b, Keith J. Gaddie^c, Ken Truman^d, and Jamie L. Kistler^e

^aBiogen, Cambridge, MA, USA ^bMerck & Co., Inc., Kenilworth, NJ, USA ^cVertex Pharmaceuticals, Boston, MA, USA ^dMedThink SciCom, Cary, NC, USA ^eParexel International, Newton, MA, USA *Affiliation at time of survey development, data collection, and data analysis: MedThink SciCom.

Poster 38

Join us for a candid conversation with the authors

KEY FINDINGS

- Experience with formal assessment of SCPs, particularly externally focused metrics, was limited among ISMPP survey respondents
- Potential barriers cited included organizational structure, logistics, budget, and lack of familiarity with defining appropriate metrics
- Industry professionals generally agreed that it would be of value to define a series of metrics, including both internally

CONCLUSIONS

- Survey results indicated general alignment regarding how to define SCP success but reveal a lack of consistency in how to define and implement specific metrics to assess this success in a meaningful way
- Although various barriers have precluded broad adoption of SCP metrics to date, respondents acknowledged the value of designing appropriate metrics and d a desire to learn how to define and implement app etrics through

and external success of

METHODS

	ISMPP survey questions*	
We conducted	1 What is your current affiliation?	erience in SCP ISMPP Connect forums;
under defin	2 Please provide the name of your organization. Note: organization names are requested to help understand the range of opinions and experiences represented in this survey; individual responses will not be tied to specific organizations in any analysis or subsequent presentation.	I networks nd 12/14/2020 ::
asses	3 How many SCPs have you facilitated the development of in the past 3 years? [Directly or in collaboration with pharmaceutical or biotechnology clients]	or large pharmaceutical
to imp	4 Is your organization [or the organizations with which you are currently working to develop SCPs] currently using a web-based platform to host the SCP(s)?	academia,
RESULTS Response rate 91 respondents	5 After development and implementation of an SCP, does your organization [or the organizations with which you work] formally assess any metrics related to the SCP? For the purposes of this question, metrics may be quantitative (eg, number of SCP views on a digital platform) or qualitative (eg, monitoring use of the lexicon in internal communications).	lementation of the SCP bles with the SCP, and
 Of these, ~20 pl provided response 	6 Regarding internally focused quantitative or qualitative metrics related to the SCP, which of the following do you measure? Please select all that apply.	s an SCP? In an ideal world,
experience with Limited respon minimal experie	7 Regarding externally focused quantitative or qualitative metrics related to the SCP, which of the following do you measure? Please select all that apply.	al respondents are shown.
using formal me Survey respondents reported to assess success of the	8 Please provide additional details on how you conduct the following assessments: use of the lexicon by individuals outside of the organization (quantitative assessment, such as through targeted literature analyses); use of the lexicon by individuals outside of the organization (qualitative assessment, such as through interviews of internal stakeholders about their experiences during scientific engagement); external citations of company-sponsored	exicon and scientific story pert as demonstrated communication activities of the company
Use of specific metrics to respondents reported cur	manuscripts; other; we do not currently assess any externally focused quantitative or qualitative metrics.	
respondents reported that	9 How do you define the success of an SCP? In an ideal world, what type of information would you want to be able to measure to assess this success?	on across all functions and of the internal team
	10 What do you perceive as barriers to the development and implementation of relevant metrics designed to assess the success of an SCP? Please select all that apply.	external facing ons are aligned to the
Pharmaceutical Respondents: Does your organization	11 Through which of the following venues would you be interested in learning about the development and implementation of metrics designed to assess the success of an SCP? Please select all that apply.	fic statements, lexicon, es
formally assess any metrics related to the SCP? ^a	12 Is there anything else you would like to share? For example, do you have a case study describing how you have implemented metrics to assess the success of an SCP within your organization or an organization with which you work closely? If you would like to be contacted for a follow-up discussion, please include your name and email.	
	*Table provides a general summary of survey questions (actual questions were specifically tailored for "pharmaceutical" or "nonpharmaceutical" respondents).	
^a Data represent proportion of responses fro	rom 20 pharmaceutical respondents who answered this question.	

Data represent proportion of responses from 20 pharmaceutical resp ^bData represent proportion of responses from 30 nonpharmaceutical respondents who answered this question.

Commonly reported metrics used included visits to a web-based SCP (pharmaceutical 3/6 [50%]; nonpharmaceutical, 6/11 [55%]) and assessment of lexicon use within internal documents (pharmaceutical, 1/6 [17%]; nonpharmaceutical 6/11 [55%]) and external documents (pharmaceutical, 3/6 [50%]; nonpharmaceutical, 5/11 [45%])

0	

•

Use of externally focused metrics was very low among respondents, suggesting limited experience to date; survey respondents primarily cited literature tracking and manual analysis to report on language/lexicon utilization Developing an SCP is a large undertaking, which can often take a significant • amount of time, resources, and/or budget. While metrics are extremely important to demonstrate the impact of such an initiative, they are not always consistently defined (not really followed through on at the completion of the SCP). It would be important to really define, for each team involved in SCP development and implementation, what success might look like and how they want to measure success as part of the early stages of SCP development. Should really include metrics as part of the overall project plan and think about how these assessments might be carried out after final implementation.

– ISMPP Survey Respondent

ACKNOWLEDGMENTS The authors wish to thank all ISMPP survey participants for their time and valuable insights, as well as Parexel International for editorial, graphics, digital, and production support in the development of this interactive poster and MedThink SciCom for editorial and graphics support for our corresponding ISMPP Annual Meeting parallel session.

Gretchen S. Chidester^{a*}, Boyd B. Scott^b, Keith J. Gaddie^c, Ken Truman^d, and Jamie L. Kistler^e

^aBiogen, Cambridge, MA, USA ^bMerck & Co., Inc., Kenilworth, NJ, USA ^cVertex Pharmaceuticals, Boston, MA, USA ^dMedThink SciCom, Cary, NC, USA ^eParexel International, Newton, MA, USA *Affiliation at time of survey development, data collection, and data analysis: MedThink SciCom.

Poster 38

Join us for a candid conversation with the authors

KEY FINDINGS

- Experience with formal assessment of SCPs, particularly externally focused metrics, was limited among ISMPP survey respondents
- Potential barriers cited included organizational structure, logistics, budget, and lack of familiarity with defining appropriate metrics
- Industry professionals generally agreed that it would be of value to define a series of metrics, including both internally


CONCLUSIONS

- Survey results indicated general alignment regarding how to define SCP success but reveal a lack of consistency in how to define and implement specific metrics to assess this success in a meaningful way
- Although various barriers have precluded broad adoption of SCP metrics to date, respondents acknowledged the value of designing appropriate metrics and indicated a desire transition how to define and implement appropriate metrics through the value of how to define and implement appropriate metrics through the value of how to define and implement appropriate metrics.

RESULTS


Survey respondent demographics: experience with SCP development

Survey question: How many SCPs have you [or the organizations with which you are currently working] facilitated the development of in the past 3 years?



Survey respondent demographics: experience with SCP web-based platforms

Survey question: Is your organization [or the organizations with which you are currently working] currently using a web-based platform to host SCPs?



ACKNOWLEDGMENTS The authors wish to thank all ISMPP survey participants for their time and valuable insights, as well as Parexel International for editorial, graphics, digital, and production support in the development of this interactive poster and MedThink SciCom for editorial and graphics support for our corresponding ISMPP Annual Meeting parallel session.

Gretchen S. Chidester^{a*}, Boyd B. Scott^b, Keith J. Gaddie^c, Ken Truman^d, and Jamie L. Kistler^e

^aBiogen, Cambridge, MA, USA ^bMerck & Co., Inc., Kenilworth, NJ, USA [°]Vertex Pharmaceuticals, Boston, MA, USA ^dMedThink SciCom, Cary, NC, USA ^eParexel International, Newton, MA, USA *Affiliation at time of survey development, data collection, and data analysis: MedThink SciCom.

Poster 38

Join us for a candid conversation with the authors

KEY FINDINGS

- Experience with formal assessment of SCPs, particularly externally focused metrics, was limited among ISMPP survey respondents
- Potential barriers cited included organizational structure, logistics, budget, and lack of familiarity with defining appropriate metrics
- Industry professionals generally agreed that it would be of value to define a series of metrics, including both internally and externally focused assessments, to measure the success of an SCP



CONCLUSIONS

- Survey results indicated general alignment regarding how to define SCP success but reveal a lack of consistency in how to define and implement specific metrics to assess this success in a meaningful way
- Although various barriers have precluded broad adoption of SCP metrics to date, respondents acknowledged the value of designing appropriate metrics and indicated a desire to learn how to define and implement appropriate metrics through future ISMPP educational programs

INTRODUCTION

We conducted a survey of ISMPP membership to:



understand how industry professionals define the success of SCPs






METHODS

- A survey targeting industry professionals with experience in SCP development was posted to ISMPP LinkedIn and ISMPP Connect forums; authors also posted the survey link to professional networks
- Responses were collected between 11/24/2020 and 12/14/2020
- Survey respondents were categorized into groups:
 - "Pharmaceutical": affiliated with small/midsize or large pharmaceutical companies, or medical device companies
 - "Nonpharmaceutical": affiliated with medical communications

Survey respondents reported limited use of internally focused metrics

Survey question: Regarding internally focused quantitative or qualitative metrics related to the SCP, which of the following does your organization [or the organizations with which you work] measure? Please select all that apply.*



ACKNOWLEDGMENTS The authors wish to thank all ISMPP survey participants for their time and valuable insights, as well as Parexel International for editorial, graphics, digital, and production support in the development of this interactive poster and MedThink SciCom for editorial and graphics support for our corresponding ISMPP Annual Meeting parallel session.

Gretchen S. Chidester^{a*}, Boyd B. Scott^b, Keith J. Gaddie^c, Ken Truman^d, and Jamie L. Kistler^e

^aBiogen, Cambridge, MA, USA ^bMerck & Co., Inc., Kenilworth, NJ, USA ^cVertex Pharmaceuticals, Boston, MA, USA ^dMedThink SciCom, Cary, NC, USA ^eParexel International, Newton, MA, USA *Affiliation at time of survey development, data collection, and data analysis: MedThink SciCom.

Poster 38

Join us for a candid conversation with the authors

KEY FINDINGS

- Experience with formal assessment of SCPs, particularly externally focused metrics, was limited among ISMPP survey respondents
- Potential barriers cited included organizational structure, logistics, budget, and lack of familiarity with defining appropriate metrics
- Industry professionals generally agreed that it would be of value to define a series of metrics, including both internally and externally focused assessments, to measure the success of an SCP



CONCLUSIONS

- Survey results indicated general alignment regarding how to define SCP success but reveal a lack of consistency in how to define and implement specific metrics to assess this success in a meaningful way
- Although various barriers have precluded broad adoption of SCP metrics to date, respondents acknowledged the value of designing appropriate metrics and indicated a desire to learn how to define and implement appropriate metrics through future ISMPP educational programs

INTRODUCTION

We conducted a survey of ISMPP membership to:



understand how industry professionals define the success of SCPs



assess current trends regarding use of metrics



identify barriers to implementation of formal metrics

Limited responses to some key question



METHODS

- A survey targeting industry professionals with experience in SCP development was posted to ISMPP LinkedIn and ISMPP Connect forums; authors also posted the survey link to professional networks
- Responses were collected between 11/24/2020 and 12/14/2020
- Survey respondents were categorized into groups:
 - "Pharmaceutical": affiliated with small/midsize or large pharmaceutical companies, or medical device companies
 - "Nonpharmaceutical": affiliated with medical communications agencies, other solutions provider companies, academia, publisher, other



How do ISMPP members define success of an SCP?




- 91 respondents from >35 different organizations initiated the survey
- Of these, ~20 pharmaceutical and ~30 nonpharmaceutical respondents provided responses to key questions of interest and reported having recent experience with the development of SCPs
- Across groups, SCP success was defined as consistent implementation of the SCP into cross-functional workstreams, alignment of key deliverables with the SCP, and adoption of select SCP components by external stakeholders

Responses to survey question, "How do you define the success of an SCP? In an ideal w what type of information would you want to be able to measure to assess this succe Representative examples from pharmaceutical and nonpharmaceutical respondents are

Survey respondents reported limited use of externally focused metrics

Survey question: Regarding externally focused quantitative or qualitative metrics related to the SCP, which of the following does your organization [or the organizations with which you work] measure? Please select all that apply.



ACKNOWLEDGMENTS The authors wish to thank all ISMPP survey participants for their time and valuable insights, as well as Parexel International for editorial, graphics, digital, and production support in the development of this interactive poster and MedThink SciCom for editorial and graphics support for our corresponding ISMPP Annual Meeting parallel session.

Gretchen S. Chidester^{a*}, Boyd B. Scott^b, Keith J. Gaddie^c, Ken Truman^d, and Jamie L. Kistler^e

^aBiogen, Cambridge, MA, USA ^bMerck & Co., Inc., Kenilworth, NJ, USA [°]Vertex Pharmaceuticals, Boston, MA, USA ^dMedThink SciCom, Cary, NC, USA ^eParexel International, Newton, MA, USA *Affiliation at time of survey development, data collection, and data analysis: MedThink SciCom.

Poster 38

Join us for a candid conversation with the authors

KEY FINDINGS

- Experience with formal assessment of SCPs, particularly externally focused metrics, was limited among ISMPP survey respondents
- Potential barriers cited included organizational structure, logistics, budget, and lack of familiarity with defining appropriate metrics
- Industry professionals generally agreed that it would be of value to define a series of metrics, including both internally and externally focused assessments, to measure the success of an SCP



CONCLUSIONS

- Survey results indicated general alignment regarding how to define SCP success but reveal a lack of consistency in how to define and implement specific metrics to assess this success in a meaningful way
- Although various barriers have precluded broad adoption of SCP metrics to date, respondents acknowledged the value of designing appropriate metrics and indicated a desire to learn how to define and implement appropriate metrics through future ISMPP educational programs













Value of Metrics to Assess SCP Success

[One of the first SCPs] was created in 2005 leading up to the development and approval of a product for the treatment of type II diabetes. While the purpose and process remain unchanged some 15 year later, we have to do a better job measuring the impact of developing a platform, and we have to ensure those supporting the development of a platform truly know how to create, vet, and implement an [SCP], and measure the value. Only when this is fully adhered to will we see genuine case studies with best practices for measuring its value.

erience in SCP SMPP Connect forums; networks nd 12/14/2020

r large pharmaceutical

mmunications cademia,



- 91 respondents
- Of these, ~20 pl provided respon experience with
- Limited respon minimal experie using formal me

Survey respondents repo to assess success of the

Use of specific metrics t respondents reported cur respondents reported that



^aData represent proportion of responses ^bData represent proportion of response

- Commonly reported me (pharmaceutical 3/6 [50% of lexicon use within inte nonpharmaceutical 6/11 3/6 [50%]; nonpharmace
- Use of externally focuse suggesting limited exper literature tracking and ma



- ISMPP Survey Respondent

Novel Ideas: Thinking Ahead to the Future of SCPs

We are looking into how we can enhance the use and experience of a scientific platform and even linking it with a strategic pub plan, using AI enabled chatbots. It is very much in the beginning stages or prototyping and conceptualization, but the idea is to make the information accessible based on real-time needs...

- ISMPP Survey Respondent

Interest in Future ISMPP Educational Initiatives

- Poster presentation at a future ISMPP meeting
- Workshop/course at a future ISMPP meeting
- Parallel presentation at a future ISMPP meeting
- Roundtable at a future ISMPP meeting
- ISMPP U webinar or podcast program
- Case studies

A comprehensive course (with certificate of satisfactory completion) sharing [best practices] for development of a scientific platform, the impact on supporters of the asset, the metrics required to prove the value and [demonstrate consistent use and implementation]...

- ISMPP Survey Respondent

ementation of the SCP ples with the SCP, and

n SCP? In an ideal world, assess this success?" respondents are shown.

exicon and scientific story ert as demonstrated communication activities of the company

n across all functions and of the internal team

xternal facing ons are aligned to the c statements, lexicon,

e a significant 8 ktremely important vays consistently SCP). It would evelopment and ant to measure Id really include these assessments

spondent

ACKNOWLEDGMENTS The authors wish to thank all ISMPP survey participants for their time and valuable insights, as well as Parexel International for editorial, graphics, digital, and production support in the development of this interactive poster and MedThink SciCom for editorial and graphics support for our corresponding ISMPP Annual Meeting parallel session.